Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a significant milestone in the clinical development of ... Read More
New hope for asthma and eczema? Akeso’s latest antibody AK139 enters clinical trials
Akeso, Inc. (9926.HK) has announced a major milestone with the acceptance of its Investigational New Drug (IND) application for AK139 by the China National Medical ... Read More
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking a significant advancement in immunotherapy research. The ... Read More
Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment
Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step in its mission to redefine first-line treatment ... Read More
Akeso’s Gumokimab poised to redefine Psoriasis treatment
Akeso, Inc., a leading biopharmaceutical innovator based in Hong Kong, is making significant strides in the treatment of autoimmune diseases. The company recently announced that ... Read More
Chinese biopharma company Akeso raises $150m for antibody drug discovery
Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a ... Read More